Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $120,091.01 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard Geary sold 1,601 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $75.01, for a total transaction of $120,091.01. Following the sale, the executive vice president owned 59,657 shares in the company, valued at approximately $4,474,871.57. The trade was a 2.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $73.55 on Monday. The stock has a 50-day moving average price of $67.11 and a two-hundred day moving average price of $48.37. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $76.78. The stock has a market cap of $11.91 billion, a PE ratio of -43.52 and a beta of 0.33. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. The company had revenue of $157.00 million during the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.Ionis Pharmaceuticals’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IONS. Citigroup raised their price target on shares of Ionis Pharmaceuticals from $69.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday, September 3rd. Wells Fargo & Company raised their target price on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an “overweight” rating in a research report on Friday, August 22nd. Cowen set a $99.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. Raymond James Financial restated a “strong-buy” rating and set a $89.00 price objective (up from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. Finally, Needham & Company LLC lifted their target price on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.65.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several large investors have recently modified their holdings of IONS. GSA Capital Partners LLP acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at about $665,000. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Ionis Pharmaceuticals by 161.3% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 155,790 shares of the company’s stock worth $10,192,000 after acquiring an additional 96,164 shares during the period. denkapparat Operations GmbH bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $652,000. State of New Jersey Common Pension Fund D grew its position in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 59,817 shares of the company’s stock valued at $3,913,000 after purchasing an additional 899 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 6.2% during the third quarter. PNC Financial Services Group Inc. now owns 12,113 shares of the company’s stock worth $792,000 after purchasing an additional 702 shares during the period. 93.86% of the stock is owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.